GOTHENBURG, Sweden, April 20, 2021 /PRNewswire/ — Vicore Pharma Holding AB (publ) (“Vicore”), a pharmaceutical firm creating revolutionary medicines for extreme lung issues akin to idiopathic pulmonary fibrosis (IPF), right this moment introduced that it’ll host a key opinion chief (KOL) webinar on C21, the corporate’s lead asset for the remedy of COVID-19, on Wednesday, April 28, 2021 at 14:00 CET (8 am EST).
The occasion will function a presentation by KOL Professor Maureen Horton, M.D., Johns Hopkins College College of Medication, who will talk about the present remedy panorama and unmet medical wants in treating sufferers with COVID-19. Professor Horton will likely be out there to reply questions following the conclusion of the occasion.
Vicore’s Chief Medical Officer, Rohit Batta may also give an replace on the outcomes from the section II research in COVID-19 and share the design of the upcoming section III pivotal research with their lead drug candidate, C21, an angiotensin II kind 2 receptor (AT2R) agonist. C21 can be being investigated in a section II research in Idiopathic Pulmonary Fibrosis (IPF) and has orphan drug designation on this indication from the regulatory authorities in Europe and the USA.
To register for the webinar, please click on here.
Maureen Horton, M.D. is Professor of Medication and Environmental Well being Engineering at Johns Hopkins College College of Medication in Baltimore, MD, Co-Director of the Interstitial Lung Illness Program within the division of Pulmonary and Vital Care Medication, and an attending doctor on the Johns Hopkins Hospital Medical Intensive Care Unit.
Professor Horton’s analysis goals to know the immunological dysregulation that promotes lung damage and fibrosis. Following earlier work wherein she developed a novel vaccine-induced immunotherapy remedy for lung fibrosis, her analysis continues to find novel metabolic therapies for each lung fibrosis and acute respiratory misery syndrome (ARDS). She has been the principal investigator or website PI in roughly 10 scientific trials of therapies for lung illness and has over 80 publications on pulmonary situations together with IPF, IPF cough, and lung fibrosis in addition to respiratory infections akin to influenza and COVID-19.
Since 2020, Professor Horton has been concerned in a number of research immune dysregulation in COVID-19 infections and is co-author of latest publication figuring out distinct T cell and myeloid cells related to acutely unwell COVID-19 sufferers, offering essential mechanistic perception into the pathogenesis of COVID-19.
Professor Horton obtained her MD from Johns Hopkins College College of Medication and undertook her internship, residency and fellowship coaching in Pulmonary and Vital Care Medication on the Johns Hopkins Hospital. She is triple board licensed in Inside Medication, Pulmonary and Vital Care Medication.
For additional info:
Carl-Johan Dalsgaard, CEO
Tel: +46 70 975 98 63
E: [email protected]
This info was submitted for publication on April 20, 2021 at 08:00 CET.
This info was dropped at you by Cision http://news.cision.com
The next recordsdata can be found for obtain:
SOURCE Vicore Pharma Holding AB